Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
Community Pharmacy Scotland has agreed on a three-year contract deal with the Scottish Government to secure funding for community pharmacy north of the border for the next three years.
The deal involves investment in the overall global sum, investment in the development of independent pharmacist prescribers and also investment in the development of a career pathway for community pharmacists through the foundation programme.
A three-year settlement for the period 2020-21 to 2022-23. The remuneration Global Sum will be subject to a fixed percentage uplift of 2.5% in each of the three years. The remuneration Global Sum in 2020-21 will be reset at £188.148 million.
NHS Pharmacy First Scotland service
The introduction of a new NHS Pharmacy First Scotland service and associated remuneration model, replacing the existing Minor Ailment Service and Pharmacy First, from April 2020. The Scottish Government will invest a total of £10 million of new funding over three-year period. An initial investment in 2020-21 of £5 million, increasing to £7.5 million in 2021-22 and in 2022-23 a total of £10 million will be added to the remuneration Global Sum.
Taken alongside the existing funding for MAS and the repurposing of agreed existing funding of £5 million, the total funding pot available in the financial year 2020-21 for the service will be £25.8 million.
Agreement was reached to support the principle of the continuation of additional mapped funding as part of the proposed 3-year settlement. The sum of £40 million will continue to be mapped from Part 7 (generic) Drug Tariff as guaranteed income.
Any amounts mapped as guaranteed funding during the proposed 3-year settlement will be equal to any amount of money due to NHS Boards through the margin sharing arrangements. Based on the projected end year position, this is likely to be in the region of £25 million. Taken alongside already agreed mapped guaranteed income in year 2018-19 and 2019-20 (£40 million), a total in the region of £65 million will be mapped as guaranteed income. Any agreed amount mapped as guaranteed income is not subject to an annual uplift.
The total guaranteed funding to be delivered in 2020-21 is £258.148 million.
Any additional income earned above the guaranteed minimum or an agreed amount in 2020-21 will be shared on a 50 : 50 basis between NHS Boards and community pharmacy owners.
All parties are agreed on the preferred mechanism to deliver any amount due to Boards for sharing will be a reduction in the value of Part 7 (generic) Drug Tariff additional. The clawback arrangements will cease from April 2020.
Independent pharmacist prescribers
The non-Global Sum will remain at £1.3 million and will be repurposed towards funding infrastructure to support the joint SG and CPS strategy of increasing the number of independent prescriber workforce within the community pharmacy setting. To support the Independent Prescribing Strategy and Career Pathway for community pharmacy funding of £3.258 million will be made available to pharmacy contractors.
Career pathway for community pharmacists
Funding will be made available to pharmacy owners to support pharmacists completing the NES Foundation Programme. The Scottish Government and CPS have set aside an agreed budget of £1.44 million in 2020-21 increasing to £4.32 million in 2022-23 for the purposes of supporting pharmacists complete the NES Foundation programme. This will be deployed from 2020-21 subject to all the operational elements being in place to allow this to go ahead.
The Scottish Government will explore the use of existing Pharmacy Champions funding in developing closer working between community pharmacy and Health and Social Care Partnerships.
Director of Operations at Community Pharmacy Scotland Matt Barclay commented:
“The CPS Board were satisfied that the three-year deal, a first for the pharmacy network, was correct under the terms negotiated with Rose Marie and her team.
“This gives real opportunity to focus on making a success of the NHS Pharmacy First service, which has been the focus of our recent membership engagement on the road, alongside developing a coherent career framework and independent prescribing strategy for community pharmacy.
“These opportunities, alongside the initial investment on offer, recognises the value of pharmacy teams and the network within primary care and gives a platform on which we can build. We look forward to working collaboratively with stakeholders to make this happen in the coming years.”
Chief executive of the National Pharmacy Association Mark Lyonette commented:
“This is a vote of confidence in Scottish community pharmacy and will lead to a significant improvement in patient access to NHS healthcare.
“The Scottish Government, pharmacy negotiators and pharmacy teams across Scotland are working in partnership to develop services in line with a clear strategy and that is to be applauded. We are especially pleased to see investment in the clinical skills of the community pharmacy workforce, which will reap rewards well beyond the three-year timeframe.
“The direction of travel towards clinical services is being underpinned by new and guaranteed funding, which shows the way for other parts of the UK to follow. The NHS, the community pharmacy sector, patients and communities will all benefit from this investment.”
You can read the full circular below. For more details on Matt Barclay’s views on Pharmacy First, you can listen to our recent podcast by clicking here. We also reported on the developments around Pharmacy Ifrst which you can access here.
This circular is being shared under the Open Government Copywrite licence.
Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.